title: [Rheumatoid arthritis (updated Current Care guideline)].
abstract: Anti-citrulline antibodies are highly specific to rheumatoid arthritis (RA) and are thus helpful in differential diagnosis. Early and aggressive disease modifying anti-rheumatic drug (DMARD) therapy is essential for a positive treatment result in cases of RA. Remission during the 1st year of treatment predicts permanent remission, milder joint damage and better functional ability. It is recommended that patients with an unsatisfactory response to DMARDs, including methotrexate and a combination of DMARDs, should be treated primarily with TNF blockers, and non-responders with rituximab or abatacept. RA is an independent risk factor for cardiovascular diseases. The assessment of cardiovascular risk must not be forgotten in daily practice.
authors: Markku
authors: M
authors: Hakala
authors: Pekka
authors: P
authors: Hannonen
authors: Tapani
authors: T
authors: Helve
authors: Markku
authors: M
authors: Korpela
authors: Kimmo
authors: K
authors: Mattila
authors: Timo
authors: T
authors: Möttönen
authors: Tiina
authors: T
authors: Varis
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology; D002956:Citrulline / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D002956:Citrulline